You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1220 Development of B cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Engineering
1220 Development of B cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Bae J, Kitayama S, Herbert Z, et al
1220 Development of B cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1220